World's Best Scientists 2026 revealed!

D-Index & Metrics

Medicine

D-Index
107
Citations
46435
World Ranking
6199
National Ranking
3304

Overview

David S. Hong is affiliated with The University of Texas MD Anderson Cancer Center in the United States. Their research spans multiple areas within medicine, with a strong focus on oncology and biochemistry, genetics, and molecular biology.

The scientist has contributed extensively to the fields of oncology, pulmonary and respiratory medicine, molecular biology, cancer research, and immunology. Their work covers a broad spectrum of topics related to cancer, including lung cancer treatments and mutations, colorectal cancer treatments and studies, cancer immunotherapy and biomarkers, cancer genomics and diagnostics, CAR-T cell therapy research, pancreatic and hepatic oncology research, and immunotherapy and immune responses.

David S. Hong has published a significant number of papers, with frequent contributions in the following journals:

  • Journal of Clinical Oncology
  • Annals of Oncology
  • Cancer Research
  • Regular and Young Investigator Award Abstracts
  • Clinical Cancer Research

Their recent papers illustrate a focus on targeted cancer therapies and clinical trials. Notable works include:

  • KRAS G12C Inhibition with Sotorasib in Advanced Solid Tumors, 2020, New England Journal of Medicine
  • Larotrectinib in patients with TRK fusion-positive solid tumours: a pooled analysis of three phase 1/2 clinical trials, 2020, The Lancet Oncology
  • Phase 1 study of MRX34, a liposomal miR-34a mimic, in patients with advanced solid tumours, 2020, British Journal of Cancer

David S. Hong collaborates frequently with several researchers, including:

  • Funda Meric-Bernstam
  • Sarina A. Piha-Paul
  • Siqing Fu
  • Daniel D. Karp
  • Apostolia M. Tsimberidou

Their research contributions significantly engage with advanced cancer therapies, biomarker identification, and molecular mechanisms underlying cancer progression and treatment response.

Best Publications

  • Efficacy of Larotrectinib in TRK Fusion–Positive Cancers in Adults and Children

    Alexander Drilon;Theodore W. Laetsch;Shivaani Kummar;Steven G. DuBois

  • The clinical KRAS(G12C) inhibitor AMG 510 drives anti-tumour immunity

    Jude Canon;Karen Rex;Anne Y. Saiki;Christopher Mohr

  • KRASG12C Inhibition with Sotorasib in Advanced Solid Tumors.

    David S. Hong;Marwan G. Fakih;John H. Strickler;Jayesh Desai

  • Autophagy as a target for anticancer therapy

    Filip Janku;David J. McConkey;David S. Hong;Razelle Kurzrock

  • Larotrectinib in patients with TRK fusion-positive solid tumours: a pooled analysis of three phase 1/2 clinical trials

    David S Hong;Steven G DuBois;Shivaani Kummar;Anna F Farago

  • Phase I study of MRX34, a liposomal miR-34a mimic, administered twice weekly in patients with advanced solid tumors

    Muhammad S. Beg;Andrew J. Brenner;Jasgit Sachdev;Mitesh Borad

  • Phase 1 study of MRX34, a liposomal miR-34a mimic, in patients with advanced solid tumours.

    David S. Hong;Yoon Koo Kang;Mitesh Borad;Jasgit Sachdev

  • Activity of XL184 (cabozantinib), an oral tyrosine kinase inhibitor, in patients with medullary thyroid cancer

    Razelle Kurzrock;Steven I. Sherman;Douglas W. Ball;Arlene A. Forastiere

  • Personalized Medicine in a Phase I Clinical Trials Program: The MD Anderson Cancer Center Initiative

    Apostolia M. Tsimberidou;Nancy G. Iskander;David S. Hong;Jennifer J. Wheler

  • Interleukin-6 and its receptor in cancer: implications for translational therapeutics

    David S. Hong;Laura S. Angelo;Razelle Kurzrock

  • Mutation Profiling in Cholangiocarcinoma: Prognostic and Therapeutic Implications

    Chaitanya R. Churi;Rachna Shroff;Ying Wang;Asif Rashid

  • Feasibility of Large-Scale Genomic Testing to Facilitate Enrollment Onto Genomically Matched Clinical Trials

    Funda Meric-Bernstam;Lauren Brusco;Kenna Shaw;Chacha Horombe

  • Randomized Trial of Irinotecan and Cetuximab With or Without Vemurafenib in BRAF-Mutant Metastatic Colorectal Cancer (SWOG S1406)

    Scott Kopetz;Katherine A. Guthrie;Van K. Morris;Heinz Josef Lenz

  • AZD9150, a next-generation antisense oligonucleotide inhibitor of STAT3 with early evidence of clinical activity in lymphoma and lung cancer

    David Sanghyun Hong;Razelle Kurzrock;Youngsoo Kim;Richard Woessner

  • PIK3CA Mutations in Patients with Advanced Cancers Treated with PI3K/AKT/mTOR Axis Inhibitors

    Filip Janku;Apostolia Maria Tsimberidou;Ignacio Garrido-Laguna;Xuemei Wang

  • 2-Fluoro-2-deoxy-D-glucose positron emission tomography imaging is predictive of pathologic response and survival after preoperative chemoradiation in patients with esophageal carcinoma.

    Stephen G. Swisher;Jeremy Erasmus;Mary Maish;Arlene M. Correa

  • Combining Radiation and Immunotherapy: A New Systemic Therapy for Solid Tumors?

    Chad Tang;Xiaohong Wang;Hendrick Soh;Steven Seyedin

  • Lymphopenia association with gross tumor volume and lung V5 and its effects on non-small cell lung cancer patient outcomes.

    Chad Tang;Zhongxing Liao;Daniel Gomez;Lawrence Levy

  • Ipilimumab with Stereotactic Ablative Radiation Therapy: Phase I Results and Immunologic Correlates from Peripheral T Cells

    Chad Tang;James W. Welsh;Patricia de Groot;Erminia Massarelli

  • Targeting the molecular chaperone heat shock protein 90 (HSP90): lessons learned and future directions

    David Sanghyun Hong;Udai Banerji;Udai Banerji;Bahareh Tavana;Goldy C George

Frequent Co-Authors

Razelle Kurzrock
Razelle Kurzrock Medical College of Wisconsin
Filip Janku
Filip Janku The University of Texas MD Anderson Cancer Center
Sarina Anne Piha-Paul
Sarina Anne Piha-Paul The University of Texas MD Anderson Cancer Center
Apostolia Maria Tsimberidou
Apostolia Maria Tsimberidou The University of Texas MD Anderson Cancer Center
Funda Meric-Bernstam
Funda Meric-Bernstam The University of Texas MD Anderson Cancer Center
Kenneth R. Hess
Kenneth R. Hess The University of Texas MD Anderson Cancer Center
Scott Kopetz
Scott Kopetz The University of Texas MD Anderson Cancer Center
Rajyalakshmi Luthra
Rajyalakshmi Luthra The University of Texas MD Anderson Cancer Center
Michael J. Overman
Michael J. Overman The University of Texas MD Anderson Cancer Center
John V. Heymach
John V. Heymach The University of Texas MD Anderson Cancer Center

If you think any of the details on this page are incorrect, let us know.

Report an issue

We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below:

Related Online Degrees & Career Pathways

The medical field offers a broad range of degree options and career paths beyond traditional medical school. If you're interested in starting your healthcare career quickly, adn nursing programs provide a fast track to becoming a registered nurse, often with flexible admission criteria.

For those who prefer a non-clinical path, healthcare administration is a popular choice. A healthcare administration degree can open doors to management roles in hospitals, clinics, and other medical facilities, with many accredited programs available fully online.

Students seeking even more accessible options should consider nursing school that don't require teas. These programs eliminate common standardized test barriers, making entry smoother for aspiring nurses.

Additionally, medical billing and coding schools that accept fafsa give students a pathway into healthcare administration and records, often with financial aid options.

Each of these online degrees presents flexible and rewarding opportunities to enter and advance in the healthcare sector.

Best Scientists Citing David S. Hong

Trending Scientists

Recently Published Articles